Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.
Filipe Azevedo MouraDavid D BergAndrea BellaviaJamie P DwyerLawrence A LeiterBenjamin M SciricaStephen D WiviottDeepak L BhattItamar RazMark W FeinbergEugene BraunwaldDavid A MorrowMarc S SabatinePublished in: Diabetes care (2023)
Risk models for kidney disease progression can be applied in patients with T2D to stratify risk and identify those who experience a greater magnitude of benefit from SGLT2 inhibition.